Considering that nanobodies targeting HER2 (NCT04467515) and BCMA (as NbCAR-T cells) (NCT03664661) have reached clinical trials, nanobody-based NK cell engagers targeting HER2 and BCMA have more chance to be effective against HER2+ solid tumors and multiple myeloma, respectively. The gene discussed is ERBB2; the disease is plasma cell myeloma.